Hydroxyurea enhances the activities of didanosine, 9- [2(phosphonylmethoxy)ethyl]adenine, and 9-[2(phosphonylmethoxy)propyl] adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 2046-2050

  Palmer, Sarah ^a,b   Shafer, Robert W ^a   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ISOLATION;

EID: 0032854838     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.2046     Document Type: Article

References (38)

1. Arts, E. J., and M. A. Wainberg. 1994. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 38:1008-1016.
2. Balzarini, J., L. Naesens, J. Slachmuylders, H. Niphuis, I. Rosenberg, A. Holy, H. Schellekens, and E. De Clercq. 1991. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5:21-28.
3. Balzarini, J., T. Vahlenkamp, H. Egberink, K. Hartmann, M. Witvrouw, C. Pannecouque, P. Casara, J. F. Nave, and E. De Clercq. 1997. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrob. Agents Chemother. 41:611-616.
4. Bianchi, V., E. Pontis, and P. Reichard. 1986. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. 261:16037-16042.
5. Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamedi-Sangsari, and J. Vila. 1995. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:36-40.
6. Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamedi-Sangsari, and J. Vila. 1996. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antivir. Res. 29:111-113.
7. De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903.
8. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
9. Donehower, R. C. 1992. An overview of the clinical experience with hydroxyurea. Semin. Oncol. 19(Suppl. 9):11-19.
10. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90:8925-8928.
11. Gao, W.-Y., D. G. Johns, S. Chokekijchai, and H. Mitsuya. 1995. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 92:8333-8337.
12. Gao, W.-Y., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:767-772.
13. Gao, W. Y., H. Mitsuya, J. S. Driscoll, and D. G. Johns. 1995. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2′-beta-fluoro-2′,3′-dideoxyadenosine in peripheral blood mononuclear cells. Biochem. Pharmacol. 50:274-276.
14. Hurta, R. A., and J. A. Wright. 1990. Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells. Biochem. Biophys. Res. Commun. 167:258.
15. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
16. Johns, D. G., and W. Y. Gao. 1998. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem. Pharmacol. 55:1551-1556.
17. Lori, F., H. Jessen, A. Foli, J. Lisziewicz, and P. S. Matteo. 1997. Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 277:1437-1438. (Letter.)
18. Lori, F., A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805.
19. Lori, F., A. G. Malykh, A. Foli, R. Maserati, A. De Antoni, L. Minoli, D. Padrini, A. Degli Antoni, E. Barchi, H. Jessen, M. A. Wainberg, R. C. Gallo, and J. Lisziewicz. 1997. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. Hum. Retroviruses 13:1403-1409.
20. Miller, M. D., P. D. Lamy, M. D. Fuller, A. S. Mulato, N. A. Margot, T. Cihlar, and J. M. Cherrington. 1998. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol. Pharmacol. 54:291-297.
21. Myers, G., B. Korber, B. Foley, K.-T. Jeang, J. W. Mellors, and S. Wain-Hobson. 1996. Human retroviruses and AIDS 1996: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.M.
22. Nicander, B., and P. Reichard. 1985. Relations between synthesis of deoxyribonucleotides and DNA replication in 3T6 fibroblasts. J. Biol. Chem. 260:5376-5381.
23. Nijhuis, M., C. A. B. Boucher, and R. Schuurman. 1995. Sensitive procedure for amplification of HIV-1 RNA using a combined reverse transcriptase and amplification reaction. BioTechniques 19:178-182.
24. Palmer, S., and S. Cox. 1997. Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob. Agents Chemother. 41:460-464.
25. Palmer, S., J. Hannenberg, and S. Cox. 1996. Synergistic inhibition of HIV isolates (including 3′-azido-3′-deoxythymidine-resistant isolates) by foscarnet in combination with 2′,3′-dideoxyinosine or 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 48:1285-1288.
26. Pauwels, R., J. Balzarini, D. Schols, M. Baba, J. Desmyter, I. Rosenberg, A. Holy, and E. De Clercq. 1988. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1025-1030.
27. Robbins, B. L., J. Greenhaw, M. C. Connelly, and A. Fridland. 1995. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob. Agents Chemother. 39:2304-2308.
28. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42:612-617.
29. Schapiro, J. M., M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. 1996. The effect of high-dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
30. Shafer, R. W., M. A. Winters, S. Palmer, and T. C. Merigan. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated HIV-1 infected patients. Ann. Intern. Med. 128:906-911.
31. Sharma, P. L., and C. S. Crumpacker. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71:8846-8851.
32. Smith, M. S., E. L. Brian, E. De Clercq, and J. S. Pagano. 1989. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 33:1482-1486.
33. Soramadossi, J. P. 1993. Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16(Suppl. 1):S7-S15.
34. Tracewell, W. G., D. L. Trump, W. P. Vaughan, D. C. Smith, and P. R. Gwilt. 1995. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother. Pharmacol. 35:417-422.
35. Vila, J., F. Biron, F. Nugier, T. Vallet, and D. Peyramond. 1996. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 348:203-204. (Letter.)
36. Vila, J., F. Nugier, G. Bargues, T. Vallet, D. Peyramond, F. Hamedi-Sangsari, and J. M. Seigneurin. 1997. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350:635-636. (Letter.)
37. Villani, P., R. Maserati, M. B. Regazzi, R. Giacchino, and F. Lori. 1996. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J. Clin. Pharmacol. 36:117-121.
38. Winters, M. A., J. M. Schapiro, J. Lawrence, and T. C. Merigan. 1998. HIV-1 protease genotypes and in vitro protease inhibitor susceptibility from long-term saquinavir-treated individuals who switched to other protease inhibitors. J. Virol. 72:5303-5306.